There is compelling evidence to implicate dopamine in the etiology of obsessive compulsive disorder (OCD). Administration of amphetamine (Ellinwood, 1967) phenmetrazine and L dopa produces obsessive symptoms. Furthermore, a recent study indicated in Tourette's syndrome patients, fluvoxamine worsened tics, coprolalia and OCD but the addition of pimozide improved both OCD and tics (McDougle et al., 1990). Patients with tic spectrum disorder and premorbid schizoid personality responded to this drug. Pimozide alone improved tics and not OCD (Delgado et al., 1990). These findings indicate that a hyperdopaminergic state as well as serotonin mechanism may play a role in the pathogenesis in OCD.
Contrary to the above mentioned findings, patients with parkinson's disease, encephalitis lethargica or Sydenham's chorea manifest OCD, indicating that a deficency of dopamine may be involved in its pathogenesis. In fact, Insel et al. (1983) reported a significant improvement in OCD patients treated with amphetamine. Therefore there is evidence for both dopamine excess and deficiency in OCD. We used a dopamine release inhibitor-cholecystokinin (CCK-8) and a dopaminergic drug -methylphenidate in OCD patients to assess their efficacy in the management of this disorder.
Three patients wefe selected based on a diagnosis of OCD with a minimum score of 20 on the Yale Brown Obsessive Compulsive Symptom Scale (YBOCS), absence of clinical depression, good physical health, illness duration of two years or more, and normal EEG and MRI. The exclusion criteria were a history of head injury, epilepsy, left handedness, and any acute physical illness. After obtaining informed consent, they were interviewed every two wqeeks on the basis of which the YBOCS was completed. 5 meg of CCK8 was given intravenously once every other week for a period of 12 weeks (six injections). After a two week wash out period, the same patient received methylphenidate 20 mg orally every morning for three days. During this trial, they were rated on YBOCS prior to the medication intake, and at the end of two and four hour after medication.
On CCK two patients with a YBOCS score of 22 and 24 did not change while in the third patient the YBOCS score of 22 increased to 26. In two, this trial was discontinued after six weeks. With methylphenidate, all the three patients increased rituals, obsessions, anxiety and agitation. The score of 22,24 and 26 changed to 32 (in two) and 34 after three days.
CCK-8, a dopamine release inhibitor, and methyl phenidate, a dopaminergic drug, did not produce any beneficial effects on OCD. This is in contrast to the beneficial effects of amphetamine reported by Insel et al. (1983) . The discrepancy may be due to the possibility that amphetamine and not methylphenidate is therapeutically useful. Lack of effect of cholecystokinin may be related to its rapid metabolism and inability to cross blood brain barrier. Further exploration of dopaminergic drugs to elucidate the relationship between dopamine and serotonin in OCD is warranted.
